These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study. Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149 [TBL] [Abstract][Full Text] [Related]
8. [The contrast enhancement of brain and spinal cord tumors using Gd-DTPA in magnetic resonance tomography with an extra-low magnetic-field intensity]. Kornienko VN; Pronin IN; Turkin AM; Fadeeva LM Zh Vopr Neirokhir Im N N Burdenko; 1993; (4):13-7. PubMed ID: 8296501 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Gd [DTPA-bis (2-aminoethoxy) ethane] polymeric contrast agent with gadodiamide injection for interstitial MR lymphography: experimental study with rabbits. Zhou Z; Guo J; Yu H; Zhu B; Liu C; Jiang X; Zhang M; Chen J J Magn Reson Imaging; 2005 Sep; 22(3):361-7. PubMed ID: 16106365 [TBL] [Abstract][Full Text] [Related]
11. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects. Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513 [TBL] [Abstract][Full Text] [Related]
12. The use of dynamic magnetic resonance imaging to evaluate orthotopic continent urinary diversion. Tempany CM; Masoudi FA; Marshall FF Urology; 1995 May; 45(5):886-92. PubMed ID: 7747382 [TBL] [Abstract][Full Text] [Related]
13. Clinical utility of Gd-DTPA-enhanced magnetic resonance imaging in lung cancer. Kono M; Adachi S; Kusumoto M; Sakai E J Thorac Imaging; 1993; 8(1):18-26. PubMed ID: 8418316 [TBL] [Abstract][Full Text] [Related]
14. Targeted magnetic resonance imaging with intraperitoneal and intravenous streptavidin (SA)-DTPA-Gd: a comparative study in tumor-bearing nude mice. Ye J; Xu YK; Liu X; Lü GS Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):139-43. PubMed ID: 16503514 [TBL] [Abstract][Full Text] [Related]
15. Intercellular imaging by a polyarginine derived cell penetrating peptide labeled magnetic resonance contrast agent, diethylenetriamine pentaacetic acid gadolinium. Guo YM; Liu M; Yang JL; Guo XJ; Wang SC; Duan XY; Wang P Chin Med J (Engl); 2007 Jan; 120(1):50-5. PubMed ID: 17254488 [TBL] [Abstract][Full Text] [Related]
16. Contrast-enhanced high resolution magnetic resonance imaging of pigmented malignant melanoma using Mn-TPPS4 and Gd-DTPA: experimental results. Mäurer J; Strauss A; Ebert W; Bauer H; Felix R Melanoma Res; 2000 Feb; 10(1):40-6. PubMed ID: 10711639 [TBL] [Abstract][Full Text] [Related]
17. Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors. Kubota T; Yamada K; Kizu O; Hirota T; Ito H; Ishihara K; Nishimura T J Magn Reson Imaging; 2005 Jun; 21(6):694-700. PubMed ID: 15906343 [TBL] [Abstract][Full Text] [Related]
18. [Clinical application of MRI for urological malignancy. 3: A new trial of MRI for bladder cancer and prostatic cancer; surface coil and GD-DTPA]. Nishimura K; Hida S; Nishio Y; Yoshida O; Nakano Y Hinyokika Kiyo; 1988 Dec; 34(12):2097-100. PubMed ID: 3239521 [TBL] [Abstract][Full Text] [Related]
19. MR imaging with Gd-DTPA in lesions of the head and neck. Vogl Th; Dresel S; Juergens M; Assal J; Lissner J J Otolaryngol; 1993 Aug; 22(4):220-30. PubMed ID: 8230372 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of CH3-DTPA-Gd (NMS60) as a new MR contrast agent: early phase II study in brain tumors and dual dynamic contrast-enhanced imaging. Ito M; Ogino H; Oshima H; Shiraki N; Shibamoto Y; Kasai H; Mase M; Kawamura Y; Miyati T Magn Reson Imaging; 2006 Jun; 24(5):625-30. PubMed ID: 16735185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]